These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

926 related articles for article (PubMed ID: 30736741)

  • 1. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
    Molassiotis A; Cheng HL; Lopez V; Au JSK; Chan A; Bandla A; Leung KT; Li YC; Wong KH; Suen LKP; Chan CW; Yorke J; Farrell C; Sundar R
    BMC Cancer; 2019 Feb; 19(1):132. PubMed ID: 30736741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
    Cheng HL; Molassiotis A
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Redefining chemotherapy-induced peripheral neuropathy through symptom cluster analysis and patient-reported outcome data over time.
    Wang M; Cheng HL; Lopez V; Sundar R; Yorke J; Molassiotis A
    BMC Cancer; 2019 Nov; 19(1):1151. PubMed ID: 31775665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following Chemotherapy.
    Li T; Timmins HC; Mahfouz FM; Trinh T; Mizrahi D; Horvath LG; Harrison M; Grimison P; Friedlander M; Marx G; Boyle F; Wyld D; Henderson R; King T; Baron-Hay S; Kiernan MC; Rutherford C; Goldstein D; Park SB
    JAMA Netw Open; 2024 Aug; 7(8):e2424139. PubMed ID: 39120903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes.
    Li T; Timmins HC; Trinh T; Mizrahi D; Harrison M; Horvath LG; Grimison P; Friedlander M; Kiernan MC; King MT; Rutherford C; Goldstein D; Park SB
    J Natl Compr Canc Netw; 2023 Feb; 21(2):125-132.e3. PubMed ID: 36791763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.
    Molassiotis A; Cheng HL; Leung KT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; Ng TR; Suen LKP; Chan CW; Yorke J; Lopez V
    Brain Behav; 2019 Jun; 9(6):e01312. PubMed ID: 31063261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade.
    Tan AC; McCrary JM; Park SB; Trinh T; Goldstein D
    Support Care Cancer; 2019 Dec; 27(12):4771-4777. PubMed ID: 30972648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy.
    Cheng HL; Lopez V; Lam SC; Leung AKT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; De Ng TR; Suen LKP; Chan CW; Yorke J; Molassiotis A
    Health Qual Life Outcomes; 2020 Jul; 18(1):246. PubMed ID: 32703223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy-induced peripheral neuropathy: longitudinal analysis of predictors for postural control.
    Müller J; Kreutz C; Ringhof S; Koeppel M; Kleindienst N; Sam G; Schneeweiss A; Wiskemann J; Weiler M
    Sci Rep; 2021 Jan; 11(1):2398. PubMed ID: 33504885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
    Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
    JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.
    Bao T; Seidman AD; Piulson L; Vertosick E; Chen X; Vickers AJ; Blinder VS; Zhi WI; Li Q; Vahdat LT; Dickler MN; Robson ME; Mao JJ
    Eur J Cancer; 2018 Sep; 101():12-19. PubMed ID: 30007894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy.
    McCrary JM; Goldstein D; Trinh T; Timmins HC; Li T; Friedlander M; Bosco A; Harrison M; Maier N; O'Neill S; Park SB
    J Pain Symptom Manage; 2019 Dec; 58(6):1023-1032. PubMed ID: 31374367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY).
    Tanioka H; Nagasaka T; Uno F; Inoue M; Okita H; Katata Y; Kanzaki H; Kuramochi H; Satake H; Shindo Y; Doi A; Nasu J; Yamashita H; Yamaguchi Y
    BMC Cancer; 2019 Oct; 19(1):941. PubMed ID: 31604467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer.
    Mo H; Yan X; Zhao F; Teng Y; Sun X; Lv Z; Cao M; Zhao J; Song G; Pan B; Li H; Zhai J; Xu B; Ma F
    JAMA Netw Open; 2022 Nov; 5(11):e2239788. PubMed ID: 36322088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy.
    Yeo F; Ng CC; Loh KWJ; Molassiotis A; Cheng HL; Au JSK; Leung KT; Li YC; Wong KH; Suen L; Chan CW; Yorke J; Farrell C; Bandla A; Ang E; Lopez V; Sundar R; Chan A
    Support Care Cancer; 2019 Dec; 27(12):4753-4762. PubMed ID: 30972646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).
    Kuroi K; Shimozuma K; Ohashi Y; Hisamatsu K; Masuda N; Takeuchi A; Aranishi T; Morita S; Ohsumi S; Hausheer FH
    Support Care Cancer; 2009 Aug; 17(8):1071-80. PubMed ID: 19089463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling.
    Kolb NA; Smith AG; Singleton JR; Beck SL; Stoddard GJ; Brown S; Mooney K
    JAMA Neurol; 2016 Jul; 73(7):860-6. PubMed ID: 27183099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
    Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
    Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Balance Deficits and Functional Disability in Cancer Survivors Exposed to Neurotoxic Cancer Treatments.
    McCrary JM; Goldstein D; Trinh T; Timmins HC; Li T; Menant J; Friedlander M; Lewis CR; Hertzberg M; O'Neill S; King T; Bosco A; Harrison M; Park SB
    J Natl Compr Canc Netw; 2019 Aug; 17(8):949-955. PubMed ID: 31390588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy-Induced Peripheral Neuropathy in Patients With Gastroesophageal Cancer.
    van Velzen MJM; Pape M; Sprangers MAG; van Kleef JJ; Mostert B; Beerepoot LV; Slingerland M; Gootjes EC; Hoekstra R; van de Poll-Franse LV; Haj Mohammad N; van Laarhoven HWM
    J Natl Compr Canc Netw; 2024 Jul; 22(7):455-461. PubMed ID: 38977016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.